Clinical Trial Update: A Study in Older Subject to Evaluate the Safety and Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Rivaroxaban [Phase 3]

View source ↗

Summary

Phase 3 trial assessing the safety and reversal of rivaroxaban anticoagulation by andexanet alfa in older subjects; completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bleeding

Drugs mentioned

• Andexanet alfa (andexanet alfa)
• Rivaroxaban (rivaroxaban)

Snippet

Sponsor: Portola Pharmaceuticals | Conditions: Bleeding | Phase 3 | Status: COMPLETED | Results posted: 2018-09-25